BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 25, 2022 | IPO | — | — | — | — | Detail |
Sep 17, 2019 | Private Equity(PE) | $90M | 1 | Temasek Holdings | — | Detail |
Apr 19, 2018 | Funding Round | $115M | 2 | Woodford Investment Management | — | Detail |
Aug 26, 2015 | Series Unknown | $87M | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Temasek Holdings | Yes | Private Equity(PE) |
Woodford Investment Management | Yes | Funding Round |
Goldman Sachs | — | Funding Round |
Lansdowne Partners | — | Series Unknown |
Lundbeck | — | Series Unknown |
Upsher Smith Laboratories | — | Series Unknown |